Gastroprotective effects of a new zinc(II)-curcumin complex against pylorus-ligature-induced gastric ulcer in rats.
Zn(II)-curcumin, a mononuclear (1:1) zinc complex of curcumin was synthesized and examined for its antiulcer activities against pylorus-ligature-induced gastric ulcer in rats. The structure of Zn(II)-curcumin was identified by elemental analysis, NMR and TG-DTA analysis. It was found that a zinc atom was coordinated through the keto-enol group of curcumin along with one acetate group and one water molecule. Zn(II)-curcumin (12, 24 and 48 mg/kg) dose-dependently blocked gastric lesions, significantly reduced gastric volume, free acidity, total acidity and pepsin, compared with control group (P<0.001) and curcumin alone (24 mg/kg, P<0.05). Reverse transcriptase polymerase chain reaction (RT-PCR) analysis showed that Zn(II)-curcumin markedly inhibited the induction of nuclear factor-kappa B (NF-kappaB), transforming growth factor beta(1) (TGF-beta(1)) and interleukin-8 (IL-8), compared with control group (P<0.05). These findings suggested that Zn(II)-curcumin prevented pylorus-ligation-induced lesions in rat by inhibiting NF-kappaB activation and the subsequent production of proinflammatory cytokines, indicating a synergistic effect between curcumin and zinc. An acute toxicity study showed that mice treated with SDs of Zn(II)-curcumin (2 g/kg) manifested no abnormal signs.
Mei
Xueting
X
Laboratory of Traditional Chinese Medicine and Marine Drugs, School of Life Sciences, Sun Yat-sen University, No. 135, Xin Guang Xi Road, Guangzhou 510275, China.
Luo
Xiaoju
X
Xu
Sika
S
Xu
Donghui
D
Zheng
Yanping
Y
Xu
Shibo
S
Lv
Junyi
J
D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001483:Base Sequence; D003474:Curcumin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017931:DNA Primers; D004305:Dose-Response Relationship, Drug; D016209:Interleukin-8 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011706:Pyloric Antrum; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013276:Stomach Ulcer / Q000517:prevention & control*; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000096:biosynthesis
D000897:Anti-Ulcer Agents; D017931:DNA Primers; D016209:Interleukin-8; D016328:NF-kappa B; D009942:Organometallic Compounds; D016212:Transforming Growth Factor beta; D003474:Curcumin